Yemen Health Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Yemen Health Report.

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

March 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

April 2026

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

Press releases published on January 12, 2026

Jan. 12, 2026

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance

GlobeNewswire

Jan. 12, 2026

RAD Increases Ownership in Radiopharm Ventures to 87.5%

GlobeNewswire

Jan. 12, 2026

Lyra Therapeutics Provides Corporate Update

GlobeNewswire

Jan. 12, 2026

Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD

GlobeNewswire

Jan. 12, 2026

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2025

GlobeNewswire

Jan. 12, 2026

Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire

Jan. 12, 2026

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

GlobeNewswire

Jan. 12, 2026

MediWound Provides Corporate Update and Financial Outlook Ahead of the J.P. Morgan Healthcare Conference

GlobeNewswire

Jan. 12, 2026

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

GlobeNewswire

Jan. 12, 2026

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire

Jan. 12, 2026

Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth

GlobeNewswire

Jan. 12, 2026

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

GlobeNewswire

Jan. 12, 2026

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

GlobeNewswire

Jan. 12, 2026

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

GlobeNewswire

Jan. 12, 2026

Precede Biosciences Secures $83.5M in Total Financing to Scale Next-Generation Precision Diagnostics Platform

GlobeNewswire

Jan. 12, 2026

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

GlobeNewswire

Jan. 12, 2026

Sotera Health to Showcase Continued Revenue Growth and Strategic Value Creation at 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire

Jan. 12, 2026

Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications

GlobeNewswire

Jan. 12, 2026

Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026

GlobeNewswire

Jan. 12, 2026

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases

GlobeNewswire